Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology
Bibliographic record
Abstract
In the article that accompanies this editorial, the results of three clinical trials in patients with non–small-cell lung cancer (NSCLC) are reported. An important aim of an editorial can be to evaluate whether the design of the trial and the methods used to analyze the results permit readers to draw definitive conclusions that inform clinical practice or guide the development of future clinical trials. Each of these articles raises important issues about trial methodology that the reader may not have had the time to think about and that could influence the interpretation of the results. Ipilimumab is an exciting new targeted agent which specifically blocks the binding of cytotoxic T-lymphocyte antigen-4 (CTLA-4) to its ligands. This blockade augments T-cell activation leading to tumor regression. Ipilimumab was recently shown to improve survival in patients with advanced melanoma. 1,2 Lynch et al 3 conducted a randomized phase II trial in patients with NSCLC to estimate the additional activity of ipilimumab over chemotherapy alone using immune-related progression-free survival (irPFS) as an outcome measure. The use of a placebo for ipilimumab and the double-blind design strengthened the comparison of carboplatin and paclitaxel plus the immune-targeted agent with chemotherapy alone. Another important objective of the trial was to address the scheduling of ipilimumab and chemotherapy. Two schedules were tested: (1) ipilimumab administered concurrently with chemotherapy (concurrent), and (2) two cycles of chemotherapy followed by four cycles of chemotherapy and ipilimumab together (phased). The authors reported that the phased regimen improved irPFS significantly compared with the control regimen (hazard ratio [HR] 0.72; 95% CI, 0.50 to1.06; P .05), but the concurrent regimen did not (HR 0.81; CI, 0.55 to 1.17,P .13). It is the choice of the optimal regimen that we want to comment on. Not only is the phased regimen active but so is the concurrent one. Note that both HRs are less than 1 and in the Kaplan-Meier plots, the curves for both the phased and concurrent regimens are above that of the chemotherapy control (Fig 2 in publication). A larger sample size could well have resulted in the concurrent approach being significant too. It did not appear that the rules for selecting the optimum schedule were specified a priori. Nonetheless, the conclusion to support further investigation of phased-ipilimumab plus paclitaxel/carboplatin over the concurrent-ipilimumab chemotherapy regimen seems sensible given that the “phased” arm is consistently the best for all the outcome measures, and clearly superior for the progression (PFS) outcomes.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.658 | 0.850 |
| Meta-epidemiology (narrow) | 0.003 | 0.002 |
| Meta-epidemiology (broad) | 0.008 | 0.005 |
| Bibliometrics | 0.009 | 0.007 |
| Science and technology studies | 0.004 | 0.029 |
| Scholarly communication | 0.018 | 0.018 |
| Open science | 0.009 | 0.010 |
| Research integrity | 0.013 | 0.032 |
| Insufficient payload (model declined to judge) | 0.011 | 0.005 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".